Headlines about Arcadia Biosciences (NASDAQ:RKDA) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Arcadia Biosciences earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave media headlines about the basic materials company an impact score of 46.0599388389477 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Arcadia Biosciences (NASDAQ:RKDA) opened at $0.26 on Wednesday. Arcadia Biosciences has a twelve month low of $0.23 and a twelve month high of $1.50.

Separately, Piper Jaffray Companies set a $1.00 target price on Arcadia Biosciences and gave the company a “hold” rating in a report on Saturday, July 22nd.

TRADEMARK VIOLATION NOTICE: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.watchlistnews.com/arcadia-biosciences-rkda-receives-daily-coverage-optimism-rating-of-0-15/1703654.html.

About Arcadia Biosciences

Arcadia Biosciences, Inc is an agricultural biotechnology trait company. The Company develops a portfolio of yield and traits addressing multiple crops that supply the global food and feed markets. It has a pipeline of products in development incorporating its traits, including products that are in advanced stages of development or on the market.

Insider Buying and Selling by Quarter for Arcadia Biosciences (NASDAQ:RKDA)

Receive News & Ratings for Arcadia Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.